AlphaGrep UK’s AbbVie ABBV Stock Holding History

AlphaGrep UK’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$216K	Sell	860 -539	-39%	-$116K	0.06%	661
2026 Q1	$304K	Sell	1,399 -1,741	-55%	-$386K	0.09%	499
2025 Q4	$717K	Buy	+3,140	New	+$715K	0.24%	96

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

AlphaGrep UK's ABBV Position: Q2 2026 in Review

AlphaGrep UK reduced its AbbVie (ABBV) stake by 39% in Q2 2026, selling an estimated $116K and leaving 860 shares worth $216K. The position accounts for 0.06% of the portfolio, ranked #661.

AlphaGrep UK first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. The position peaked at $717K in Q4 2025. 4,063 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

AlphaGrep UK held 860 shares of AbbVie worth $216K as of Q2 2026.
AlphaGrep UK sold 539 AbbVie shares in Q2 2026, an estimated $116K.
AbbVie made up 0.06% of AlphaGrep UK's portfolio in Q2 2026, its #661 holding.
AlphaGrep UK first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
AlphaGrep UK's AbbVie position peaked at $717K in Q4 2025.
4,063 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on AlphaGrep UK's 13F filing for Q2 2026, filed 14 Aug 2026.